SGLT-2 Inhibitors: The Magic Bullet for Cardio-Renal Protection in Type 2 DM  

作　　者：Rushi Patel Terry Oroszi Rushi Patel;Terry Oroszi(Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Wright State University, Fairborn, OH, USA)

机构地区：[1]Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Wright State University, Fairborn, OH, USA

出　　处：《Pharmacology & Pharmacy》2024年第12期490-507,共18页药理与制药(英文)

摘　　要：Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are a promising class of medications for type 2 diabetes mellitus (DM2) treatment. This study aims to evaluate the clinical efficacy, safety, and potential benefits of SGLT-2 inhibitors in improving cardiovascular and renal outcomes in DM2 patients. A comprehensive review of clinical trials and studies on SGLT-2 inhibitors was conducted. SGLT-2 inhibitors significantly improve glycemic control, reduce cardiovascular mortality, and lower the risk of renal events in DM2 patients. SGLT-2 inhibitors offer substantial cardio-renal protection in DM2 management, though further research is needed to optimize their use.Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are a promising class of medications for type 2 diabetes mellitus (DM2) treatment. This study aims to evaluate the clinical efficacy, safety, and potential benefits of SGLT-2 inhibitors in improving cardiovascular and renal outcomes in DM2 patients. A comprehensive review of clinical trials and studies on SGLT-2 inhibitors was conducted. SGLT-2 inhibitors significantly improve glycemic control, reduce cardiovascular mortality, and lower the risk of renal events in DM2 patients. SGLT-2 inhibitors offer substantial cardio-renal protection in DM2 management, though further research is needed to optimize their use.

关 键 词：SGLT-2 Inhibitors Type 2 Diabetes Mellitus Cardiovascular Outcomes Renal Protection Glycemic Control 

分 类 号：R58[医药卫生—内分泌]